fashion -WSS

fashion

author：entertainment 2025-09-06 07:17:30 - browse：6

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Congress might make insulin pumps more accessible to the blind

WSS

Here’s what’s in the FDA plan to include pregnant women in clinical trials

First Opinion Podcast: What happens when kids become caregivers?

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Congress must protect the remaining independent doctors

Congress must protect the remaining independent doctors

Scientists successfully use ultrasound imaging to map brain activity

focus

fashion

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Report cites 'urgent' need to recruit more diverse clinical trial participants

Activists slam private health insurers over coverage restrictions

Dark money group runs ads on China biotech bill

Wildfire smoke exposes gaps in outdoor worker protections

Adam's Biotech Scorecard: Do Sarepta's exon

Virginia high school admissions case could be legal follow

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

AMAs digital advisors table RPM coding reform proposal, again

Congress might make insulin pumps more accessible to the blind

Report cites 'urgent' need to recruit more diverse clinical trial participants

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Ebola vaccine can save some who are already sick, per new study

leisure time

focus

hotspot

focus